ATS Medical, Inc.
ATSI
NASDAQ4.00
USD
+0.01
- -
CIK
0000824068
Return %
Stock
S&P500
1Y
- -
17.85
3Y
- -
64.56
5Y
- -
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 245
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 3905 Annapolis Lane N Minneapolis United States of America 55447
- IPO Date
- Apr 20, 2000
- CIK
- 0000824068
- Website
- atsmedical.com
- Similar Companies
- Business
- ATS Medical, Inc. (Nasdaq: ATSI) develops and manufactures products for the cardiac surgery market, focusing on heart valve therapy and surgical cryoablation; its core offerings include mechanical and biological heart valves such as the ATS Open Pivot heart valves for aortic and mitral valve replacement, ATS 3f tissue heart valves, Simulus semi-rigid annuloplasty rings for valve repair, CryoMaze cryoablation systems for treating cardiac arrhythmias, and related surgical tools and accessories including robotic surgery products. Founded in 1991 and headquartered in Minneapolis, Minnesota, the company operates globally across more than 60 countries with subsidiaries in Europe and Asia. In 2010, ATS Medical was acquired by Medtronic, Inc. for approximately $370 million, integrating its technologies into Medtronic's structural heart disease portfolio; earlier, it acquired CryoCath Technologies' surgical cryoablation business in 2007 for $22 million and received FDA approval for the ATS Simulus annuloplasty ring.